Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Billing Codes · Pharmacy · Oncology, Pulmonology, HematologyMedium impact

MA08.125d, Lurbinectedin (Zepzelca®)

Act
by Jun 1, 2026
Effective date
Jun 1, 2026
Identified
Jun 19, 2026

Summary

Independence Blue Cross updated MA08.125d to remove specific lung cancer ICD-10 diagnosis codes (C33, C34.xx series) and now requires providers to report the most appropriate diagnosis code supporting medical necessity criteria. Coverage for Lurbinectedin (Zepzelca®) for small cell lung cancer treatment remains substantively unchanged, but diagnosis code reporting is now more flexible and less prescriptive. This change affects all SCLC claims billed under this policy effective June 1, 2026.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Jun 1, 2026 · 5 steps
01Billing team must update claim submission and verification processes to remove restrictions on ICD-10 codes C33 and C34.00-C34.92 for Lurbinectedin (Zepzelca®) claims.
02Update billing system templates and prior authorization requests to allow any appropriate ICD-10 diagnosis code that supports medical necessity criteria per the policy (SCLC diagnosis).
03Ensure providers document the specific SCLC diagnosis code with claim submissions.
04Communicate to oncology providers that they should report the most specific and appropriate diagnosis code reflecting the patient's condition rather than selecting from a fixed code list.
05No prior authorization workflow changes are required; coding flexibility increases claim processing efficiency.

Codes mentioned

J9223

Original notice

MA08.125d, Lurbinectedin (Zepzelca®)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.125c, Lurbinectedin (Zepzelca®)LowNo effective date · Pharmacy08.01.67c, Lurbinectedin (Zepzelca®)LowNo effective date · Pharmacy08.01.67d, Lurbinectedin (Zepzelca®)MediumEffective Jun 1, 2026 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesOncologyPulmonologyHematologyCode J9223

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account